SCHEMBL10104460

SCHEMBL10104460

Cc1cc(CN2CCCCC2)c(Cl)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.43
ALDH1A1 P00352 7/20 0.43
POLB P06746 2/20 0.42
CRHR1 P34998 2/20 0.41
ATM Q13315 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GAA P10253 1/20 0.39
CACNA1B Q00975 5/20 0.39
CACNB4 O00305 4/20 0.39
CACNA1A O00555 4/20 0.39
CACNA1G O43497 4/20 0.39
CACNG3 O60359 4/20 0.39
CACNA1F O60840 4/20 0.39
CACNA1H O95180 4/20 0.39
CACNB3 P54284 4/20 0.39
CACNA2D1 P54289 4/20 0.39
CACNG7 P62955 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104431 0.98 KDM4E (0.43) KDM4EALDH1A1POLBCRHR1ATM
SCHEMBL10104470 0.95 KDM4E (0.46) KDM4EALDH1A1POLBCRHR1ATM
SCHEMBL10104463 0.87 NR1H2 (0.53) KDM4EALDH1A1POLBATMTDP1
SCHEMBL10104450 0.86 CYP2A13 (0.44) CRHR1ATMTDP1MEN1KMT2A
SCHEMBL10104480 0.85 KDM4E (0.43) KDM4EALDH1A1POLBCRHR1ATM
SCHEMBL10104533 0.83 KDM4E (0.44) KDM4EALDH1A1POLBCRHR1ATM
SCHEMBL10104436 0.82 RORC (0.46) KDM4EALDH1A1ATMTDP1MEN1
SCHEMBL10104479 0.82 KDM4E (0.43) KDM4EALDH1A1POLBCRHR1ATM
SCHEMBL10104461 0.80 S1PR1 (0.37) KDM4EALDH1A1ATMTDP1MEN1
SCHEMBL10104455 0.80 SCN9A (0.40) KDM4EATMTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 KDM4E 2715/4885ALDH1A1 175/4885POLB 3682/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 KDM4E 1224/4885ALDH1A1 860/4885POLB 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.